DexCom, Inc. (DXCM)
What changed in recent filings
- Revenue +13% YoYQuarter ended Jun 30, 2026
- Institutions — 2 new · 3 added · 1 reduced13F · as of end of 2026 Q2
What changed in recent SEC filings — factual, not a buy/sell recommendation.
DexCom, Inc. recent earnings releases
Based on SEC filings. The release date is the day the earnings filing (8-K) was accepted; for quarters where that filing was not found, the periodic report filing date is shown.
- 26Q2Released Jul 30, 2026Revenue +13.1% YoY · EPS $0.64Released after the close: Jul 30 close → Jul 31 close, the stock moved +12.0% · over the same window, market +0.7% · sector -0.5%
- 26Q1Released Apr 30, 2026Revenue +15.0% YoY · EPS $0.51Released after the close: Apr 30 close → May 1 close, the stock moved +3.0% · over the same window, market +0.3% · sector -1.0%
- 25Q4Released Feb 12, 2026Revenue +13.1% YoY · EPS $0.67Released after the close: Feb 12 close → Feb 13 close, the stock moved +7.6% · over the same window, market +0.1% · sector +1.3%
- 25Q3Released Oct 30, 2025Revenue +21.6% YoY · EPS $0.70Released after the close: Oct 30 close → Oct 31 close, the stock moved -14.6% · over the same window, market +0.3% · sector +0.0%
The next earnings release is estimated around Oct 29, 2026 (calculated from how long this company has taken between quarter end and filing; it is not a date announced by the company).
Institutions holding DexCom, Inc.
How many of the institutions we track reported holding this stock, quarter by quarter.
2019 Q1: 3 → 2026 Q2: 7 institutions
Counts the 52 institutions we track that reported holding this stock — their full reported holdings, not just the largest positions. Not the total number of institutional holders in the US. Figures are as of quarter-end and disclosed up to 45 days later. Descriptive only — not investment advice.
Which institutions hold DexCom, Inc.
Institutions we track that reported holding this stock in their most recent 13F.
- Baillie Gifford & Co0.90% of portfolio · held as of 2019 Q1 or earlier
- National Pension Service (Korea)0.03% of portfolio · since 2019 Q2
- Bridgewater Associates0.11% of portfolio · since 2020 Q3
- Caisse de depot (Quebec)0.01% of portfolio · since 2021 Q2
- Point72 Asset Management0.02% of portfolio · since 2025 Q3
- BlackstoneNew this quarterunder 0.01% of portfolio · since 2026 Q2
- PRIMECAP ManagementNew this quarter0.01% of portfolio · since 2026 Q2
Based on 13F filings — quarter-end holdings, disclosed up to 45 days later. Holding a stock is a fact we report, not a recommendation to buy or sell.
Q2 2026 13F recap — stocks several institutions bought and sold together →Company overview
DexCom Inc. is a medical device company focused on continuous glucose monitoring systems for diabetes and metabolic health. Dexcom develops wearable biosensors, transmitters, receivers, and software that provide real-time glucose readings, trend data, and alerts to help users and clinicians monitor glucose levels without routine fingerstick testing. Its current product lineup includes Dexcom G7, Dexcom G7 15 Day, Dexcom G6, Dexcom ONE+, Stelo, Dexcom Share, and Dexcom Follow, along with digital tools and remote monitoring features that support daily diabetes management. The company serves people with diabetes, adults with prediabetes and type 2 diabetes who do not use insulin, and healthcare professionals across the United States and international markets. Headquartered in San Diego, California, DexCom plays a significant role in the diabetes care technology market through its focus on connected glucose sensing and data-sharing solutions.
What is the Biotech & Health sector?
Pharma, biotech, and medical devices. Driven by trial-result events.
DexCom, Inc. is classified under the Biotech & Health sector. See peers below.
DexCom, Inc. key financials
Based on SEC filings · as of Jun 30, 2026
Tap a metric name to see its meaning in the glossary.
DexCom, Inc. vs Biotech & Health sector benchmark
Median of 38 representative sector stocks · SEC filings · factual comparison (not advice)
A simple comparison to the sector benchmark. Higher or lower doesn’t mean good/bad or buy/sell.
DXCM revenue by segment summary
SEC 10-Q · segment totals cross-checked against total revenue
2026-06-30 revenue was $1.3B, +13.1% YoY.
The largest segment is US, 71.3% of revenue — a highly concentrated structure.
Recent revenue growth was led mainly by the US segment (about 61% of the increase).
Full segment weights, YoY changes, and an AI synthesis are available in the detailed analysis.
DXCM segment revenue mix trend
Quarterly change in segment revenue share · verified from SEC filings
ETFs holding DexCom, Inc.
Per SEC N-PORT · 2026-06-30 · by weight · factual
DXCM on Stocklore
- Revenue by segment — segment weights verified from SEC filings, YoY changes, growth drivers and concentration
- Financials & earnings quality — 6 metrics (FCF conversion, ROIC, net debt, etc.) to gauge profit quality
- 13F institutional holdings — holdings and weight changes of major institutions (45-day delay)
- Sector-relative metrics — Valuation and growth compared with the Biotech & Health average
Peers · Biotech & Health
DXCM FAQ
What is DexCom, Inc. (DXCM)?
DexCom Inc. is a medical device company focused on continuous glucose monitoring systems for diabetes and metabolic health. Dexcom develops wearable biosensors, transmitters, receivers, and software that provide real-time glucose readings, trend data, and alerts to help users and clinicians monitor glucose levels without routine fingerstick testing. Its current product lineup includes Dexcom G7, Dexcom G7 15 Day, Dexcom G6, Dexcom ONE+, Stelo, Dexcom Share, and Dexcom Follow, along with digital tools and remote monitoring features that support daily diabetes management. The company serves people with diabetes, adults with prediabetes and type 2 diabetes who do not use insulin, and healthcare professionals across the United States and international markets. Headquartered in San Diego, California, DexCom plays a significant role in the diabetes care technology market through its focus on connected glucose sensing and data-sharing solutions.
What sector is DexCom, Inc. in?
DexCom, Inc. is classified under Biotech & Health. Pharma, biotech, and medical devices. Driven by trial-result events.
What are DexCom, Inc.'s key financials?
As of Jun 30, 2026 in SEC filings: Revenue growth (YoY) 15.5%, Operating margin 24.3%, Net margin 20.1%, ROE 30.5%. Definitions and interpretation are available on Stocklore.
What are DexCom, Inc.'s main revenue segments?
The largest segment is US, about 71.3% of revenue. Segment totals are cross-checked against total revenue from SEC filings.
Where can I analyze DexCom, Inc. (DXCM) stock?
On Stocklore you can see DXCM's financials & earnings quality, 13F institutional holdings, and sector-relative metrics in one place. This page is for information and tools — not a buy/sell recommendation.
Data sources: SEC EDGAR (financials & filings), 13F (institutional holdings, as of quarter-end), market data. This page is for information and analysis tools — it does not recommend buying or selling any security. Investment decisions and responsibility are your own.